Recent Finacing
Recent Raise
Inventprise develops high‑valent conjugate vaccines using a proprietary linker platform, advancing IVT‑25 (25‑valent pneumococcal vaccine) through preclinical and Phase 1/2 trials, with pipeline for HPV, GBS, meningococcus, and SARS‑CoV‑2.
